SEC Form 3 · accession 0001209191-18-005223
Yarrow Bioscience, Inc. · YARW
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven L Basta
Officer — Chief Executive Officer · Director
Period of report
Jan 24, 2018
Accepted (ET)
Jan 24, 2018 · 6:40 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001566044
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 65,320 | I | By Basta Revocable Trust dated August 4, 2017 | |
| Common StockF1 | holding | — | — | — | 252,085 | I | By The Shelter Trust under the Basta Revocable Trust | |
| Common StockF1 | holding | — | — | — | 18,535 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1,F2 | $1.83 | holding | — | — | — | — | Feb 2, 2026 | Common Stock | 371,641 | — | D |
| Stock OptionF1,F3 | $4.83 | holding | — | — | — | — | Aug 24, 2027 | Common Stock | 84,909 | — | D |
Explanation of responses
- F1Reflects a 1-for-2.6975 reverse stock split of the Issuer's capital stock effected on January 8, 2018.
- F2The original option grant was exercisable for 390,716 shares of the Issuer's common stock. This option began vesting over a period of four years, with 1/48th of the shares subject to the option vesting monthly. The original option was subject to an early exercise provision and was immediately exercisable.
- F3The shares subject to the option will vest over a period of four years, with 1/48th of the shares subject to the option vesting monthly. The option is subject to an early exercise provision and is immediately exercisable.